Pediatrix Medical Group, Inc. (MD)

In the past six months, Pediatrix reported its second-quarter 2025 earnings with an EPS of $0.46 on August 5, 2025. On August 18, 2025, the Board authorized a share repurchase program of up to $250 million. On November 3, 2025, the company reported strong third-quarter results with earnings of $0.84 per share and raised its full-year Adjusted EBITDA outlook. Following the positive Q3 earnings report and news of a proposed two-year extension of key Obamacare subsidies, Pediatrix Medical Group's stock price was up 6.6% on November 27, 2025. On December 26, 2025, the share price reached $21.87, a 65.56% increase from its price on December 30, 2024.

Information explicitly detailing the demand seasonality for Pediatrix Medical Group, Inc.'s products and services was not found in the provided search results. The demand for hospital-based physician services is generally determined by a national market.

Pediatrix Medical Group, Inc. operates in the Healthcare sector, focusing on specialized physician services, primarily in hospital settings. The company provides neonatal care, maternal-fetal care, pediatric subspecialty care, and pediatric primary and urgent care clinics. They emphasize high-acuity, hospital-based care, with neonatology as a significant revenue source.

Pediatrix Medical Group operates in 36 to 37 states across the United States, partnering with nearly 400 hospitals and over 4,400 affiliated clinicians.

Pediatrix Medical Group's reputation has been positively influenced by its operational performance and strategic focus. The company emphasizes quality improvement and patient safety, supported by investments in research and education. Strong financial results and the proposed extension of Obamacare subsidies also contribute positively. The company is undergoing a strategic portfolio restructuring, divesting non-core practices to focus on higher-margin hospital-based services.

Pediatrix Medical Group, Inc. has a mixed ownership structure, with approximately 73.77% held by institutional investors, 1.25% by insiders, and 24.98% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and State Street Corp.